Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Peripheral T-cell Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02106650
What this trial is testing

Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies

Who this might be right for
Relapsed Peripheral T-Cell LymphomaRefractory Peripheral T-Cell Lymphoma
Acrotech Biopharma Inc. 36
Testing effectiveness (Phase 2)Study completedNCT01177371
What this trial is testing

High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Megakaryoblastic Leukemia (M7)+70 more
Case Comprehensive Cancer Center 13
Large-scale testing (Phase 3)Study completedNCT03703375
What this trial is testing

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Who this might be right for
Lymphoma, T-Cell
Celgene 93
Testing effectiveness (Phase 2)Looking for participantsNCT06854653
What this trial is testing

PTX 100 in Patients With Relapsed/Refractory CTCL

Who this might be right for
CTCL
Prescient Therapeutics, Ltd. 115
Large-scale testing (Phase 3)Study completedNCT01482962
What this trial is testing

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Who this might be right for
Relapsed Peripheral T-Cell LymphomaRefractory Peripheral T-Cell Lymphoma
Millennium Pharmaceuticals, Inc. 271
Early research (Phase 1)Study completedNCT00569283
What this trial is testing

Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant

Who this might be right for
Cancer
Asan Medical Center 18
Early research (Phase 1)Looking for participantsNCT06934382
What this trial is testing

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Who this might be right for
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Stephan Grupp MD PhD 33
Early research (Phase 1)Looking for participantsNCT07143929
What this trial is testing

To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL

Who this might be right for
CD7 Positive R/R PTCL
Peking University People's Hospital 18
Testing effectiveness (Phase 2)Study completedNCT03372057
What this trial is testing

Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Peripheral T-cell Lymphoma
SecuraBio 156
Testing effectiveness (Phase 2)Study completedNCT02927925
What this trial is testing

Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type

Who this might be right for
Lymphoma
Janssen Research & Development, LLC 32
Testing effectiveness (Phase 2)Looking for participantsNCT06874946
What this trial is testing

Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL

Who this might be right for
Precursor T-Cell Lymphoblastic Leukemia-LymphomaT - Cell LymphomaPTCL
Peking University People's Hospital 30
Testing effectiveness (Phase 2)Ended earlyNCT00625729
What this trial is testing

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
Masonic Cancer Center, University of Minnesota 6
Testing effectiveness (Phase 2)Study completedNCT03534180
What this trial is testing

Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

Who this might be right for
Anaplastic Large Cell LymphomaRecurrent Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRefractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center 12
Early research (Phase 1)Study completedNCT00513474
What this trial is testing

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+4 more
Massachusetts General Hospital 46
Testing effectiveness (Phase 2)Ended earlyNCT00655668
What this trial is testing

A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma

Who this might be right for
T-cell Non-Hodgkin's Lymphoma
Celgene 54
Early research (Phase 1)UnknownNCT00006100
What this trial is testing

Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Milton S. Hershey Medical Center
Large-scale testing (Phase 3)Not Yet RecruitingNCT05700448
What this trial is testing

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Who this might be right for
Extranodal NK/T-cell Lymphoma
CStone Pharmaceuticals 150
Large-scale testing (Phase 3)Looking for participantsNCT06776952
What this trial is testing

A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Who this might be right for
Relapsed/Refractory Peripheral T Cell Lymphoma
Evopoint Biosciences Inc. 120
Very early researchUnknownNCT06224049
What this trial is testing

Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T

Who this might be right for
T-cell Lymphoma
BGI, China 6
Testing effectiveness (Phase 2)Study completedNCT02953652
What this trial is testing

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Peripheral T-Cell Lymphoma (PTCL)
HUYABIO International, LLC. 55
Next Page